| 秦 牛,周 鑫,杨晓俊,李亚男,钱祝银.CA19-9及CA72-4联合检测在胰腺癌诊断中的应用价值[J].现代生物医学进展英文版,2019,19(23):4463-4465. |
| CA19-9及CA72-4联合检测在胰腺癌诊断中的应用价值 |
| Clinical Value of Combined Detection of Serum CA19-9 andCA72-4 Levels for the Diagnosis of Pancreatic Cancer |
| Received:May 28, 2019 Revised:June 23, 2019 |
| DOI：10.13241/j.cnki.pmb.2019.23.014 |
| 中文关键词: 血清CA19-9 CA72-4 联合检测 胰腺癌 特异性诊断 |
| 英文关键词: CA19-9 CA72-4 Combined detection Pancreatic cancer Specificity diagnosis |
| 基金项目:江苏省卫计委"六个一工程"科研项目(LGY2017081) |
| Author Name | Affiliation | | QIN Niu | Pancreatic Center, second affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, 211161, China | | ZHOU Xin | Pancreatic Center, second affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, 211161, China | | YANG Xiao-jun | Pancreatic Center, second affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, 211161, China | | LI Ya-nan | Pancreatic Center, second affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, 211161, China | | QIAN Zhu-yin | Pancreatic Center, second affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, 211161, China |
|
| Hits: 1101 |
| Download times: 612 |
| 中文摘要: |
| 摘要 目的：探究联合检测血清糖类抗原(CA)19-9和CA72-4水平在胰腺癌诊断中的应用价值。方法：回顾性选取我院2016年1月~2017年12月收治的72例胰腺癌患者作为胰腺癌组，以同期住院的68例良性胰腺病患者作为良性胰腺疾病组，同时纳入67例健康体检者作为对照组。检测三组人群血清CA19-9和CA72-4水平，采用受试者工作特征曲线(ROC曲线)及曲线下面积(AUC)分析评估各单项检测指标及联合检测指标对胰腺癌特异性诊断的价值。结果：胰腺癌组患者血清CA19-9和CA72-4水平分别为(137.69±25.32)U/mL和(6.96±1.25)U/mL，显著高于良性胰腺疾病组和对照组(P<0.05)。血清CA19-9和CA72-4联合检测诊断胰腺癌的ROC曲线AUC高于其单独检测(P<0.05)，CA19-9和CA72-4的最佳临界值分别为86.94 U/mL和4.23 U/mL，此时联合检测诊断胰腺癌的敏感性为94.7%，特异性为95.2%。结论：联合检测血清CA19-9和CA72-4诊断胰腺癌的临床价值明显优于其单独检测。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the value of combined detection of serum CA19-9 CA72-4 levels for the diagnosis of pancreatic cancer. Methods: 72 patients with pancreatic cancer in our hospital were retrospectively selected as the pancreatic cancer group from January 2016 to December 2016. 68 cases of benign pancreatic disease patients during the same period were chosen as the benign pancreatic disease group, and 67 cases of healthy physical examination people were selected as the control group. The serum levels of CA19-9 and CA72-4 were detected. The receiver-operating characteristic curve (ROC curve) and the area under curve (AUC) were employed to assess each individual and combined detection of index values for the diagnosis of pancreatic cancer. Results: The serum CA19-9 and CA72 4 levels of patients in the pancreatic cancer were (137.69±25.32) U/mL and (6.96±1.25) U/mL, which were significantly higher than those of the benign pancreatic disease group and the control group(P<0.05). The ROC curve AUC of combined detection of CA19-9 and CA72 for the diagnosis of pancreatic cancer was higher than single detection (P<0.05). The best threshold values of CA19-9 and CA72-4 were 86.94 U/mL and 4.23 U/mL. The sensitivity and specificity of combined detection for the diagnosis of pancreatic cancer were 94.7% and 95.27%. Conclusion: The clinical value of combined detection of serum CA19-9 and CA72-4 for the diagnosis of pancreatic cancer was superior to the sihgle detection. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
